50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Antithrombotic Therapy - Special Populations and Management Issues

Monday, December 8, 2008: 1:30 PM-3:00 PM

3007-3009-3011 - West (Moscone Center)

Moderators:

Marc Carrier, MD and Agnes Lee

1:30 PM

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

Alexander GG Turpie, MD¹^*, Russell D Hull, MBBS²^*, Sebastian M Schellong, MD³^*, Victor F Tapson, MD⁴^*, Manuel Monreal, MD⁵^*, Meyer Michel Samama, Prof., MD, PharmD⁶^* and Roger D Yusen, MD, MPH⁷^*

¹HHSC McMaster Clinic, McMaster University, Hamilton, ON, Canada
²Foothills Hospital, University of Calgary, Calgary, AB, Canada
³Hospital Carl Gustav Carus, Dresden, Germany
⁴Duke University Medical Center, Durham, NC
⁵Hospital Germans Trias i Pujol, Barcelona, Spain
⁶Biomnis, Ivry-sur-Seine cedex, France
⁷Washington University School of Medicine, St. Louis, MO

1:45 PM

434

Tinzaparin Compared to Unfractionated Heparin for Initial Treatment of Deep Vein Thrombosis in Very Elderly Patients with Renal Insufficiency- the IRIS Trial

Alain Leizorovicz, MD

Clinical Pharmacology, School of medicine Laennec, Lyon, France

2:00 PM

435

Interlaboratory Precision in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time

Adam Cuker¹^*, Beverly Ptashkin²^*, Barbara A. Konkle², Steven W. Pipe³, Herbert C. Whinna⁴^*, X. Long Zheng⁵, Douglas B. Cines² and Eleanor Pollak²^*

¹Hemophilia & Thromb. Prgm., Penn Presbyterian Med. Ctr., Philadelphia, PA
²University of Pennsylvania, Philadelphia, PA
³Univ. of MI Women's Hosp., Ann Arbor, MI
⁴University of North Carolina, Chapel Hill, NC
⁵Children's Hospital of Philadelphia, Philadelphia, PA

2:15 PM

436

Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery

Kenneth A. Bauer, MD¹, Martin Homering²^* and Scott D. Berkowitz, MD, FACP³

¹Beth Israel Deaconess Medical Center, Boston, MA
²Bayer HealthCare AG, Wuppertal, Germany
³Bayer HealthCare Pharmaceuticals, West Haven, CT

2:30 PM

437

Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years

Ola E Dahl¹^*, Andreas A Kurth²^*, Nadia Rosencher³^*, Janet Schnee⁴^*, Andreas Clemens⁴^*, Herbert Noack⁴^* and Bengt I Eriksson⁵^*

¹Thrombosis Research Institute, London, United Kingdom
²Orthopaedic University Hospital Stiftung Friedrichsheim, Frankfurt, Germany
³Paris 5 University, Paris, France
⁴Boehringer Ingelheim, Ingelheim, Germany
⁵Sahlgrenska University Hospital / Östra, Gothenburg, Sweden

2:45 PM

438

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

Roger D Yusen¹^*, Russell D Hull²^*, Sebastian M Schellong³^*, Victor F Tapson⁴^*, Manuel Monreal⁵^*, Michel Meyer Samama, Prof⁶^*, Min Chen⁷^* and Alexander GG Turpie⁸^*

¹Washington University School of Medicine, St. Louis, MO
²Foothills Hospital, University of Calgary, Calgary, AB, Canada
³Hospital Carl Gustav Carus, Dresden, Germany
⁴Duke University Medical Center, Durham, NC
⁵Hospital Germans Trias i Pujol, Barcelona, Spain
⁶Biomnis, 94208 Ivry-sur-Seine cedex, France
⁷Sanofi-Aventis, Bridgewater, NJ
⁸HHSC McMaster Clinic, McMaster University, Hamilton, ON, Canada

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

332.O2.6 Antithrombotic Therapy - Special Populations and Management Issues